Additional information

Notes on contributors

Mark Wagner

Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.

Jennifer Eichmeyer

Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.

Paul G. Montgomery

Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.

Jessica Monitz

Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.

Jessie Modlin

Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.

Natalie Perry

Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.